61. Autoimmune hemolytic anemia Clinical trials / Disease details


Clinical trials : 137 Drugs : 127 - (DrugBank : 55) / Drug target genes : 26 - Drug target pathways : 153

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-002844-66-IT
(EUCTR)
23/11/202123/09/2021Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic AnemiaA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia - NA Primary Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Parsaclisib (1 mg)
Product Code: [INCB050465]
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: Parsaclisib (2.5 mg)
Product Code: [INCB050465]
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: trimethoprim-sulfamethoxazole
Product Code: [trimethoprim-sulfamethoxazole]
INN or Proposed INN: TRIMETOPRIM + SULFAMETOSSAZOLO *
Product Name: pentamidine
Product Code: [pentamidine]
INN or Proposed INN: PENTAMIDINA ISETIONATO
Product Name: atovaquone
Product Code: [atovaquone]
INN or Proposed INN: ATOVAQUONE
INCYTE CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 3United States;Spain;Ukraine;Austria;Israel;United Kingdom;Italy;France;Canada;Belgium;Poland;Germany;Netherlands;Japan